Search Results

You are looking at 1 - 10 of 111 items for :

  • "cardiac hypertrophy" x
  • All content x
Clear All
Free access

Prapawadee Pirompol, Vassana Teekabut, Wattana Weerachatyanukul, Tepmanas Bupha-Intr, and Jonggonnee Wattanapermpool

prescribed level of testosterone for ergogenic aid has raised many concerns about the possible adverse effects. One important concern of testosterone action in patients and consumers is cardiac hypertrophy induction. Despite the beneficial effect on muscle

Free access

Melissa F Jackson, Dung Luong, Dor Dor Vang, Dilip K Garikipati, James B Stanton, O Lynne Nelson, and Buel D Rodgers

et al . 1999 , Shyu et al . 2006 , George et al . 2010 ). Conversely, we have recently reported that myostatin negatively regulates physiological cardiac hypertrophy ( Rodgers et al . 2009 , Valdivia 2009 ) as myostatin null ( Mstn −/− ) mice

Free access

S Jeson Sangaralingham, M Yat Tse, and Stephen C Pang

Introduction Cardiac hypertrophy (CH) is an important predictor of cardiovascular morbidity and mortality, independent of other cardiovascular risk factors. The heart adapts in response to an array of mechanical, hemodynamic

Restricted access



Severe cardiac hypertrophy has been produced experimentally in rats by long-term, lowdose treatment with tri-iodothyroacetic acid. The dose used was insufficient to cause any apparent systemic or metabolic effect. It is suggested that similar iodinated substances in the blood in man, resulting from normal or abnormal thyroid hormone catabolism, may be causally related to some forms of cardiomyopathy.

Free access

H Kobori, A Ichihara, Y Miyashita, M Hayashi, and T Saruta

We have reported previously that thyroid hormone activates the circulating and tissue renin-angiotensin systems without involving the sympathetic nervous system, which contributes to cardiac hypertrophy in hyperthyroidism. This study examined whether the circulating or tissue renin-angiotensin system plays the principal role in hyperthyroidism-induced cardiac hypertrophy. The circulating renin-angiotensin system in Sprague-Dawley rats was fixed by chronic angiotensin II infusion (40 ng/min, 28 days) via mini-osmotic pumps. Daily i.p. injection of thyroxine (0.1 mg/kg per day, 28 days) was used to mimic hyperthyroidism. Serum free tri-iodothyronine, plasma renin activity, plasma angiotensin II, cardiac renin and cardiac angiotensin II were measured with RIAs. The cardiac expression of renin mRNA was evaluated by semiquantitative reverse transcriptase-polymerase chain reaction. Plasma renin activity and plasma angiotensin II were kept constant in the angiotensin II and angiotensin II+thyroxine groups (0.12+/-0.03 and 0.15+/-0.03 microgram/h per liter, 126+/-5 and 130+/-5 ng/l respectively) (means+/-s.e.m.). Despite stabilization of the circulating renin-angiotensin system, thyroid hormone induced cardiac hypertrophy (5.0+/-0.5 vs 3.5+/-0.1 mg/g) in conjunction with the increases in cardiac expression of renin mRNA, cardiac renin and cardiac angiotensin II (74+/-2 vs 48+/-2%, 6.5+/-0.8 vs 3.8+/-0.4 ng/h per g, 231+/-30 vs 149+/-2 pg/g respectively). These results indicate that the local renin-angiotensin system plays the primary role in the development of hyperthyroidism-induced cardiac hypertrophy.

Free access

Chiung-Zuan Chiu, Bao-Wei Wang, and Kou-Gi Shyu

Introduction Cardiac hypertrophy and remodeling are considered to be compensatory processes in response to increased cardiac workload, caused by mechanical stress, hypertension, neurohumoral stimuli, myocardial injuries, or other environmental

Free access

Mario Patrizio, Marco Musumeci, Ambra Piccone, Carla Raggi, Elisabetta Mattei, and Giuseppe Marano

Introduction Pathological cardiac hypertrophy, which occurs in response to hemodynamic overload, myocardial damage, or defects in sarcomeric proteins, is associated with an enhanced risk of ventricular dysfunction and heart failure. Increased

Free access

LG Fryer, MJ Holness, JB Decock, and MC Sugden

There is evidence for a role of protein kinase C (PKC) in the development of cardiac hypertrophy. We examined the expression of individual PKC isoforms in the adult rat heart in two distinct, well-characterised in vivo models of cardiac hypertrophy associated with an activated cardiac renin-angiotensin system, namely experimental hyperthyroidism and the TGR(mRen2)27 rat. The cardiac expression of a range of PKC isoforms (PKC-alpha, PKC-omega, PKC-epsilon, PKC-gamma, and PKC-tau) was examined by immuno-blotting. Our work demonstrates that the expression of total cardiac nPKC-omega and nPKC-epsilon relative to protein is selectively and differentially modified in these models. A consistent up-regulation of nPKC-omega in conjunction with overall down-regulation of nPKC-epsilon was observed in both models. The expression of other PKC isoforms was unaffected. The divergent responses of the expression of the two nPKC isoforms to an activated cardiac renin-angiotensin system in vivo in adulthood suggest that these individual nPKC isoforms subserve specific roles in the response.

Free access

Kimberley C W Wang, Kimberley J Botting, Song Zhang, I Caroline McMillen, Doug A Brooks, and Janna L Morrison

clearance receptor for plasma IGF-2 ( Kornfeld 1992 , Powell et al . 2006 ) but is now acknowledged to induce cardiac hypertrophy ( Chu et al . 2008 , Wang et al . 2011 , 2012 a , b ). Additionally, the RAS also plays a role in cardiac hypertrophy

Free access

Wu Luo, Lan Huang, Jingying Wang, Fei Zhuang, Zheng Xu, Haimin Yin, Yuanyuan Qian, Guang Liang, Chao Zheng, and Yi Wang

panels B, C, and D; n  = 7; Treatment groups are as shown in Fig. 1; * P  < 0.05, ** P  < 0.01 compared to Ctrl; # P  < 0.05, ## P  < 0.01 compared to T1DM alone. To supplement our studies, we measured markers of cardiac hypertrophy, alpha